City

Clinical trials near Brampton, Canada

Active studies with a listed research site in Brampton, Canada.

19active studies

11recruiting now

27countries represented

321largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee

OsteoarthritisCondition

Orforglipron, PlaceboTreatment

Canada, China88 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07153471See eligibility →

Recruiting nowPhase 3

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

Type 2 DiabetesCondition

Placebo, SurvodutideTreatment

Australia, Canada121 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07754461See eligibility →

Recruiting nowPhase 3

A Study to Evaluate Effect of AZD6234 in Adult Participants With Obesity or Overweight With Weight-related Comorbidity Without Type 2 Diabetes Mellitus

Obesity or OverweightCondition

AZD6234, PlaceboTreatment

Argentina, Australia212 locations

AstraZenecaSponsor

Updated 2026-08-25 · NCT07784725See eligibility →

Recruiting nowPhase 3

A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Obesity, OverweightCondition

Eloralintide, PlaceboTreatment

Argentina, Australia162 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT07321886See eligibility →

Recruiting nowPhase 2

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

Type 2 DiabetesCondition

LY3457263, PlaceboTreatment

Canada, Germany60 locations

Eli Lilly and CompanySponsor

Updated 2026-08-21 · NCT06897475See eligibility →

Recruiting nowPhase 2

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)

Overweight, ObesityCondition

PF-08653945, PF-08653944Treatment

Canada, United States65 locations

PfizerSponsor

Updated 2026-08-17 · NCT07575932See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes

Obesity or OverweightCondition

Placebo, EnicepatideTreatment

Argentina, Australia195 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351045See eligibility →

Recruiting nowPhase 3

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

Obesity or Overweight, Type 2 Diabetes MellitusCondition

Placebo, EnicepatideTreatment

Argentina, Australia193 locations

Hoffmann-La RocheSponsor

Updated 2026-08-14 · NCT07351058See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy

Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil57 locations

AmgenSponsor

Updated 2026-08-14 · NCT07226765See eligibility →

Recruiting nowPhase 3

Maridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy

Obesity, Obstructive Sleep ApneaCondition

Maridebart cafraglutide, PlaceboTreatment

Australia, Brazil61 locations

AmgenSponsor

Updated 2026-08-04 · NCT07225686See eligibility →

Recruiting nowPhase 3

A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM

Weight ManagementCondition

Elecoglipron, PlaceboTreatment

Argentina, Australia321 locations

AstraZenecaSponsor

Updated 2026-07-10 · NCT07667803See eligibility →

Active, not recruitingPhase 3

Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Overweight, ObesityCondition

Cagrilintide, Placebo (matched to Cagrilintide)Treatment

Argentina, Canada67 locations

Novo Nordisk A/SSponsor

Updated 2026-09-04 · NCT07220759See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Obesity, OverweightCondition

Retatrutide, PlaceboTreatment

Argentina, Canada40 locations

Eli Lilly and CompanySponsor

Updated 2026-07-23 · NCT07035093See eligibility →

Active, not recruitingPhase 2

A Study of Enicepatide (CT-388) in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

Overweight or Obese, Type 2 Diabetes Mellitus (T2DM)Condition

Placebo, EnicepatideTreatment

Argentina, Canada70 locations

Carmot Therapeutics, Inc.Sponsor

Updated 2026-06-24 · NCT06628362See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight

Obesity, OverweightCondition

RetatrutideTreatment

Argentina, Canada35 locations

Eli Lilly and CompanySponsor

Updated 2026-06-09 · NCT07357415See eligibility →

Active, not recruitingPhase 3

Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Diabetes Mellitus, Type 2Condition

Retatrutide, SemaglutideTreatment

Argentina, Canada77 locations

Eli Lilly and CompanySponsor

Updated 2026-04-13 · NCT06260722See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) in the Maintenance of Weight Reduction in Individuals With Obesity

ObesityCondition

Retatrutide, PlaceboTreatment

Canada, United Kingdom53 locations

Eli Lilly and CompanySponsor

Updated 2026-03-03 · NCT06859268See eligibility →

Active, not recruitingPhase 3

Efficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight

Type 2 Diabetes Mellitus (T2DM), Obesity, OverweightCondition

Maridebart cafraglutide, PlaceboTreatment

Argentina, Bulgaria187 locations

AmgenSponsor

Updated 2025-12-31 · NCT06858878See eligibility →

Active, not recruitingPhase 2

A Research Study to Investigate the Effects of CagriSema Compared to Placebo in People With Type 2 Diabetes and Painful Diabetic Peripheral Neuropathy

Diabetes Mellitus, Type 2, Diabetic Peripheral NeuropathyCondition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

Canada, Denmark54 locations

Novo Nordisk A/SSponsor

Updated 2025-12-05 · NCT06797869See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Brampton, Canada

Current studies

Related cities